Adagio Medical Holdings, Inc Common Stock (ADGM)vsAstraZeneca PLC (AZN)
ADGM
Adagio Medical Holdings, Inc Common Stock
$0.68
-6.63%
HEALTHCARE · Cap: $10.22M
AZN
AstraZeneca PLC
$161.42
+0.88%
HEALTHCARE · Cap: $263.09B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 44792602% more annual revenue ($61.37B vs $137,000). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
ADGM
Hold36
out of 100
Grade: F
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADGM.
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.42
$35.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 75.6% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Price/Book. Revenue growth of 75.6% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 4.21 is elevated, increasing financial risk.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ADGM profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 36/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing the treatment of cardiac arrhythmias through advanced medical technologies. Utilizing its proprietary platform, the company is spearheading the development of targeted ablation techniques that address significant unmet needs in the electrophysiology sector. Supported by a robust product pipeline and a seasoned leadership team, Adagio represents an attractive investment opportunity for institutional investors seeking growth in the healthcare space while contributing to improved outcomes in cardiac patient care.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?